Ranieri G, Marech I, Lorusso V, Goffredo V, Paradiso A, Ribatti D, Gadaleta CD. Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World J Gastroenterol 2014; 20(2): 486-497 [PMID: 24574717 DOI: 10.3748/wjg.v20.i2.486]
Corresponding Author of This Article
Girolamo Ranieri, MD, Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, Cancer Institute “Giovanni Paolo II”, Via Orazio Flacco 65, 70124 Bari, Italy. giroran@tiscalinet.it
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Girolamo Ranieri, Ilaria Marech, Veronica Goffredo, Cosmo Damiano Gadaleta, Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, Cancer Institute “Giovanni Paolo II”, 70124 Bari, Italy
Vito Lorusso, Medical Oncology Unit, National Cancer Research Centre, Cancer Institute “Giovanni Paolo II”, 70124 Bari, Italy
Angelo Paradiso, Medical Oncology with Experimental Unit, National Cancer Research Centre, Cancer Institute “Giovanni Paolo II”, 70124 Bari, Italy
Domenico Ribatti, Department of Basic Medical Sciences, Neurosciences and Sensory Organs, Section of Human Anatomy and Histology, University of Bari, 70124 Bari, Italy
Author contributions: Ranieri G and Marech I contributed equally to the work; Ranieri G, Marech I and Gadaleta CD contributed to think up the manuscript and to perform the critical review of the literature; Lorusso V, Goffredo V, Paradiso A and Ribatti D contributed to literature research and data analysis. All authors wrote the manuscript.
Correspondence to: Girolamo Ranieri, MD, Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, Cancer Institute “Giovanni Paolo II”, Via Orazio Flacco 65, 70124 Bari, Italy. giroran@tiscalinet.it
Telephone: +39-80-5555561 Fax: +39-80-5555563
Received: August 11, 2013 Revised: September 26, 2013 Accepted: December 12, 2013 Published online: January 14, 2014
Core Tip
Core tip: The outcome of patients (with early or intermediate stage according to Barcelona Clinic Liver Cancer) treated with loco-regional approach alone [radiofrequency ablation (RFA) or transarterial chemoembolization (TACE)] is disappointing because the rebound of vascular endothelia growth factors induced by tissue hypoxia. On this basis there is a strong preclinical background to associate TACE or RFA with anti-angiogenic agents. We summarized the crucial role of angiogenesis and the pathways involved in hepatocellular cancer progression, underscoring the consequences of pro- and anti-angiogenic factors produced after loco-regional therapy. We explored preclinical and clinical results of trials combining molecular targeting agents plus TACE or RFA.
